TAA6-CAR-T / PersonGen Biomedicine - LARVOL DELTA

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor • CD276

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • CNS Tumor • Neuroblastoma • Oncology • Solid Tumor • CD276

Preconditioning with irradiation enhances efficacy of B7-H3-CAR-T in treating solid tumor models (ESMO 2022) - "Methods A humanized B7-H3 scFv sequence CAR-T was constructed (named TAA06)...Conclusions This study demonstrated that pre-treatment with local irradiation significantly enhanced the ability of CAR-T to infiltrate and kill tumors. The efficacy of combination therapy to treat solid tumors in patients will have to be investigated."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Neuroblastoma • Oncology • Pancreatic Cancer • Solid Tumor • CD276

Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors (Businesswire) - "Transgene...and PersonGen BioTherapeutics...announced a strategic collaboration to evaluate the feasibility and efficacy of combination therapy associating PersonGen's TAA06 CAR-T cell injection with intravenous (IV) administration of an armed oncolytic virus, from Transgene’s Invir.IO™ platform, in solid tumors including pancreatic cancer and brain glioma....Under the terms of the collaboration agreement, Transgene will develop multiple new OV candidates, using its patented oncolytic virus backbone VVcopTK-RR- and its Invir.IO™ technology platform, specifically for IV administration in combination with PersonGen's TAA06 CAR-T injection."

Licensing / partnership • Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Glioma • Oncology • Pancreatic Cancer • Solid Tumor

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Yunhui Zong

Clinical • New P1 trial • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Neuroblastoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • CD276